Kaye SB - Search Results

1

Venous thromboembolism at time of diagnosis of ovarian cancer: Survival differs in symptomatic and asymptomatic cases.

Heath OM, van Beekhuizen HJ, Nama V, Kolomainen D, Nobbenhuis MAE, Ind TEJ, Sohaib SA, Lofts FJ, Heenan S, Gore M, Banerjee S, Kaye SB, Barton DPJ. Heath OM, et al. Among authors: kaye sb. Thromb Res. 2016 Jan;137:30-35. doi: 10.1016/j.thromres.2015.11.030. Epub 2015 Nov 22. Thromb Res. 2016. PMID: 26653367

2

The role of targeted therapy in ovarian cancer.

Banerjee S, Kaye S. Banerjee S, et al. Eur J Cancer. 2011 Sep;47 Suppl 3:S116-30. doi: 10.1016/S0959-8049(11)70155-1. Eur J Cancer. 2011. PMID: 21943965 Review.

3

Progression-free survival versus overall survival in ovarian cancer: where are we now?

Banerjee S, Kaye S. Banerjee S, et al. Curr Oncol Rep. 2012 Dec;14(6):483-5. doi: 10.1007/s11912-012-0263-7. Curr Oncol Rep. 2012. PMID: 22945450 No abstract available.

4

Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).

Seifert H, Georgiou A, Alexander H, McLachlan J, Bodla S, Kaye S, Barton D, Nobbenhuis M, Gore M, Banerjee S. Seifert H, et al. Gynecol Oncol. 2015 Nov;139(2):216-20. doi: 10.1016/j.ygyno.2015.08.015. Epub 2015 Aug 28. Gynecol Oncol. 2015. PMID: 26318078

5

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.

George A, Kaye S, Banerjee S. George A, et al. Nat Rev Clin Oncol. 2017 May;14(5):284-296. doi: 10.1038/nrclinonc.2016.191. Epub 2016 Dec 13. Nat Rev Clin Oncol. 2017. PMID: 27958297 Review.

6

PARP inhibitors in BRCA gene-mutated ovarian cancer and beyond.

Banerjee S, Kaye S. Banerjee S, et al. Curr Oncol Rep. 2011 Dec;13(6):442-9. doi: 10.1007/s11912-011-0193-9. Curr Oncol Rep. 2011. PMID: 21913063 Review.

7

Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.

Han LY, Karavasilis V, Hagen Tv, Nicum S, Thomas K, Harrison M, Papadopoulos P, Blake P, Barton DP, Gore M, Kaye SB. Han LY, et al. Among authors: kaye sb. Eur J Cancer. 2010 May;46(8):1359-64. doi: 10.1016/j.ejca.2010.02.012. Epub 2010 Mar 19. Eur J Cancer. 2010. PMID: 20303743

8

The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole.

George A, McLachlan J, Tunariu N, Della Pepa C, Migali C, Gore M, Kaye S, Banerjee S. George A, et al. BMC Cancer. 2017 Jun 30;17(1):456. doi: 10.1186/s12885-017-3440-0. BMC Cancer. 2017. PMID: 28666422 Free PMC article.

9

Making the best of PARP inhibitors in ovarian cancer.

Banerjee S, Kaye SB, Ashworth A. Banerjee S, et al. Among authors: kaye sb. Nat Rev Clin Oncol. 2010 Sep;7(9):508-19. doi: 10.1038/nrclinonc.2010.116. Epub 2010 Aug 10. Nat Rev Clin Oncol. 2010. PMID: 20700108 Review.

10

Duration of second or greater complete clinical remission in ovarian cancer: exploring potential endpoints for clinical trials.

Harrison ML, Gore ME, Spriggs D, Kaye S, Iasonos A, Hensley M, Aghajanian C, Venkatraman E, Sabbatini P. Harrison ML, et al. Gynecol Oncol. 2007 Sep;106(3):469-75. doi: 10.1016/j.ygyno.2007.05.008. Epub 2007 Jul 5. Gynecol Oncol. 2007. PMID: 17614127 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

739 results

Search Page

Filters